UroGen Pharma (URGN) GC exercises RSUs, then sells shares for tax withholding
UroGen Pharma's General Counsel exercised 3,334 RSUs, converting them into ordinary shares, and sold 1,519 shares at $42.54 each to cover tax withholding. The RSUs were part of a 2023 grant of 10,000 shares, vesting in three annual installments. No 10b5-1 trading plan was reported.
How this was made
The 30-second read
Why it matters
Limited impact; typical tax withholding transaction.
Market read
Routine insider transaction with negligible trading relevance.
What to watch
Potential upcoming clinical data releases that may affect future insider activity.
Background
Form 4 filing discloses insider RSU exercise and share sale for tax purposes.
Ticker impact
General Counsel exercised 3,334 RSUs and sold 1,519 shares for tax withholding, a $65K insider sale.
Minimal price movement expected.
The transaction size ($65K) is trivial for a mid‑cap biotech and does not signal material information.
Market effects
none
none
none
Counterpoint
The sale could be interpreted as insider confidence if the executive retains a large RSU position.
Key entities
- companyUroGen Pharma
Biotech firm listed on Nasdaq (URGN).
- personJason Drew Smith
General Counsel of UroGen Pharma.
